"Game-changing RSV shot approved for infants: What you need to know"
The FDA has approved a new preventative treatment for respiratory syncytial virus (RSV), the leading cause of infant hospitalization in the US. The treatment, called Beyfortus, is a monoclonal antibody developed by Sanofi and AstraZeneca. It is approved for all infants up to 24 months and has shown efficacy in reducing hospitalizations and doctors' visits by up to 70%. The treatment offers an upgrade from the previously approved treatment, Synagis, by providing broader coverage and lasting immunity for five months. RSV puts thousands of children and elderly individuals in the hospital each year, and the new treatment is expected to have a significant impact on reducing hospitalizations and deaths.